Last mentioned: Mar 22, 2026
Clinical Guidance
Expected release of preliminary federal protocols for detransition medical management.
Type B FDA Meeting Target
Planned follow-up to define Phase III and regulatory path for AMT-130.
AMT-260 Data Readout
Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
Regulatory Review
Anticipated commencement of HHS review into federal funding for gender-affirming clinics.
Missouri Stay Request
DOJ files request in Missouri court to pause litigation pending FDA review.
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Policy Announcement
Assistant Secretary Brian Christine declares detransition care a top priority for HHS.
Document Request
Expected date for formal requests for internal FDA communications regarding DMD drug applications.
Initial Inquiry
The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
Legislative Action
Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Legislative Action
Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Investigation Announced
Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
Commissioner Consultation
Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.
Investigation Announced
Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
Commissioner Meeting
Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.
Type A FDA Meeting
Discussed AMT-130 approval pathway; alignment not yet reached.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
Earnings Call
Management confirms CMS reimbursement rate of $897 and 2025 assay expansion.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
Bioethicist Dr. John Lantos identifies a generational shift in healthcare AI, moving from specialized diagnostic tools to ubiquitous, interactive large language models. This transition is challenging the traditional authority of physicians as unregulated tools like ChatGPT and Claude become primary health resources for patients.
The rapid proliferation of large language models (LLMs) like ChatGPT and Claude is fundamentally altering the physician-patient dynamic, moving beyond traditional clinical decision support into unregulated, interactive medical consultation. Bioethicist Dr. John Lantos warns that while AI has assisted doctors for decades, the current democratization of these tools via smartphones creates a regulatory vacuum that challenges the traditional authority of medical professionals.
The integration of large language models like ChatGPT and Claude into clinical settings is fundamentally altering the traditional physician-patient relationship. Bioethicist Dr. John Lantos warns that the transition from 'invisible' diagnostic AI to 'visible' interactive AI is eroding the historical authority of doctors in a regulatory vacuum.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
HHS Assistant Secretary Brian Christine has announced that detransition care will become a primary focus for the department, marking a significant pivot in federal healthcare policy. This shift is expected to influence clinical guidelines, pharmaceutical regulation, and federal funding for gender-related medical interventions.
Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Texas Governor Greg Abbott has directed state agencies to conduct a comprehensive cybersecurity audit of medical devices manufactured in China, citing significant risks to patient data privacy. The move signals an escalation in state-level regulatory oversight of foreign-made healthcare technology and potential supply chain decoupling.
The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
A high-ranking FDA official is reportedly attempting to recruit Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, to a key agency role. The move signals a potential shift in how the FDA evaluates long-term psychiatric drug risks and has raised internal concerns regarding hiring protocols.
A senior FDA official's attempt to hire Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, has sparked debate over regulatory independence. The move could signal a more aggressive approach to drug safety labeling for common psychiatric medications, impacting pharmaceutical compliance and litigation risk.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.
A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.